Europe - Frankfurt Stock Exchange - FRA:FYB - DE000A1EWVY8 - Common Stock
The current stock price of FYB.DE is 23.175 EUR. In the past month the price increased by 1.05%. In the past year, price decreased by -57.05%.
ChartMill assigns a technical rating of 4 / 10 to FYB.DE. When comparing the yearly performance of all stocks, FYB.DE is a bad performer in the overall market: 94.63% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FYB.DE. FYB.DE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months FYB.DE reported a non-GAAP Earnings per Share(EPS) of -9.6. The EPS decreased by -339.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| Debt/Equity | 0.02 |
14 analysts have analysed FYB.DE and the average price target is 50.43 EUR. This implies a price increase of 117.62% is expected in the next year compared to the current price of 23.175.
For the next year, analysts expect an EPS growth of -86.84% and a revenue growth -8% for FYB.DE
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 62.93 | 41.67B | ||
| 1AE.DE | ARGENX SE | 64.86 | 42.73B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.31B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.03B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.97B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.92B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.81B | ||
| IVA.PA | INVENTIVA SA | N/A | 1.03B | ||
| 6IV.DE | INVENTIVA SA | N/A | 967.31M | ||
| NANO.PA | NANOBIOTIX | N/A | 873.66M | ||
| PHIL.MI | PHILOGEN SPA | 18.95 | 631.58M | ||
| AYJ.DE | VALNEVA SE | N/A | 379.92M |
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 245 full-time employees. The company went IPO on 2010-12-20. The firm is engaged in providing biosimilar drugs and formulations. The firm focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
FORMYCON AG
Fraunhoferstrasse 15, Planegg
Martinsried BAYERN DE
Employees: 250
Phone: 4989864667100
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 245 full-time employees. The company went IPO on 2010-12-20. The firm is engaged in providing biosimilar drugs and formulations. The firm focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
The current stock price of FYB.DE is 23.175 EUR. The price decreased by -3.64% in the last trading session.
FYB.DE does not pay a dividend.
FYB.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
FYB.DE stock is listed on the Frankfurt Stock Exchange exchange.
FORMYCON AG (FYB.DE) has a market capitalization of 409.50M EUR. This makes FYB.DE a Small Cap stock.
You can find the ownership structure of FORMYCON AG (FYB.DE) on the Ownership tab.